Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Summary
Study of masitinib plus docetaxel as first-line chemotherapy in men with metastatic castration-resistant prostate cancer.
Timeline
- Start
- 2014-09
- Primary completion
- 2020-12-15
- Completion
- 2020-12-15
Outcome
Met primary endpoint
release “masitinib Phase 2B/ 3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) eligible to chemotherapy met its predefined primary endpoint.” ab-science.com ↗
release “its masitinib Phase 2B/3 study (AB12003) in metastatic castrate- resistant prostate cancer (mCRPC) eligible to chemotherapy met its predefined primary endpoint.” ab-science.com ↗
release “Masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) eligible to chemotherapy met its predefined primary endpoint.” ab-science.com ↗
release “study AB12003 being a rare example of a phase 3 clinical trial that showed improvement in progression-free survival (PFS) for masitinib in combination with docetaxel.” ab-science.com ↗
release “key results from study AB12003 include: ▪ Masitinib (6.0 mg/kg/day) plus docetaxel conferred a significant progressio n-free survival (PFS) benefit in mCRPC patients” ab-science.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Masitinib | Small molecule | 6 mg/kg | Oral |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | — | — |